Across
- 1. Benign ___ Neutropenia
- 4. AFFAIRS, Not required to submit a monthly form
- 6. FREQUENCY, weekly, monthly, bi-weekly
- 9. DESIGNEE, acts on behalf of the prescriber
- 11. PD cannot enroll this type of patient
- 13. RATIONALE, indicates that the benefits of continuing clozapine treatment outweigh the risk of neutropenia and allows for dispense authorizations even though the
- 14. Updated on a monthly basis
- 15. Takes care of any insurance questions from stakeholders
- 17. SQUAD, Best squad ever
- 19. used to document ANC lab results
- 21. Day supply allowed after a patient is discharged
- 25. dispenses Clozapine to the patient
- 26. OF BIRTH, Verify the patient
- 27. has moderate or severe neutropenia
- 28. Day supply after discharge
- 29. # of authorized reps per pharmacy
- 30. stakeholder who requires a DEA #
Down
- 2. Must have this to prescribe Clozapine
- 3. STATUS, PSF will have to be submitted to resume treatment due to
- 5. PD is in unknown status due to missing a form
- 7. absolute neutrophil count (ANC) less than 500/μL.
- 8. NEUTROPHIL COUNT, Total WBC count x Total percentage of neutrophils
- 10. PR has created credentials and KA, but not the enrollment form. What's the status?
- 12. REMS, FDA-required safety program to mitigate the risk of severe neutropenia associated with the use of clozapine.
- 16. RDA is obtained for every dispense at this type of pharmacy
- 18. ASSESSMENT, Needed to certify
- 20. Legacy patients only
- 22. Only 1 RDA is needed for a patient for this type of pharmacy
- 23. A "receipt" to confirm that a pharmacist authorized the dispense in accordance with safe-use conditions
- 24. PATIENTS, New prescriber wants to add enrolled patient